Information Provided By:
Fly News Breaks for September 13, 2019
Sep 13, 2019 | 05:12 EDT
Nomura Instinet analyst Christopher Marai started Denali Therapeutics with a Buy rating and $35 price target. The analyst expects near-term upside in the shares from two readouts for the company's brain-penetrant degenogene-targeted kinase inhibitors. He believes Denali's approach reduces the traditional risk of central nervous system drug development by mirroring the precision oncology "oncogene" approach.
News For DNLI From the Last 2 Days
There are no results for your query DNLI